+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Solid Tumors Target Proteins Market - Global Forecast 2025-2030- Product Image
Solid Tumors Target Proteins Market - Global Forecast 2025-2030- Product Image
Sale

Solid Tumors Target Proteins Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 196 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6126474
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Solid tumor target proteins are redefining oncology drug development, serving as pivotal molecular gatekeepers that influence tumor progression, therapeutic accuracy, and the ability to address complex resistance pathways. With increasing demand for precision interventions in a shifting regulatory and economic landscape, senior decision-makers must identify where molecular targeting and innovative combinations converge to drive breakthroughs and maintain competitive positioning in oncology.

Market Snapshot: Solid Tumor Target Protein Landscape

The solid tumor target protein market is shaped by substantial advances in molecular biology, high-resolution structural analysis, and integrated drug design platforms. Surge in immuno-oncology, personalized therapeutics, and emerging bioengineering modalities has catalyzed the translation of protein discoveries into faster clinical development and increasingly tailored regimens. Leading market participants harness genomic profiling, proteomics, and computational modeling to discover targetable therapeutic sites, steering decision-making in product portfolios and combination therapy strategies. Regulatory frameworks are shifting toward adaptive trials, while decentralized models improve patient access and longitudinal data capture. The impact of resilience-building in supply chains, alongside evolving trade dynamics, is notable for manufacturers and biotechnology companies aiming to ensure operational continuity and cost efficiency.

Scope & Segmentation of the Solid Tumor Target Protein Market

This comprehensive report provides a segmented analysis to enable actionable insight for strategic planning and investment decisions.

  • Indication: Covers breast cancer (with HER2 positive, hormone receptor positive, and triple negative subtypes), lung cancer (non-small cell and small cell), colorectal, ovarian, and prostate cancer.
  • Target Class: Includes checkpoint inhibitors (CTLA-4, PD-1, PD-L1), DNA repair proteins, growth factor receptors (EGFR, HER2, VEGFR), kinase inhibitors (serine threonine and tyrosine), and nuclear receptors.
  • Therapeutic Modality: Profiles antibody drug conjugates, CAR T therapies, monoclonal antibodies (chimeric, fully human, humanized), and small molecules.
  • Mechanism Of Action: Examines allosteric inhibitors, DNA damage agents, hormone receptor antagonists, immune checkpoint blockers, and receptor tyrosine kinase inhibitors.
  • Regional Coverage: Analyzes the Americas (including major U.S. states, Canada, Mexico, Brazil, and Argentina), Europe, Middle East & Africa (featuring key countries across the region), and Asia-Pacific (with China, India, Japan, Australia, and other high-growth markets).
  • Company Analysis: Discusses Merck & Co., Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, AstraZeneca PLC, Pfizer Inc., Novartis AG, Johnson & Johnson, Amgen Inc., AbbVie Inc., and Sanofi S.A.

Key Takeaways for Decision-Makers

  • Precision targeting through integrated genomic and proteomic platforms enables development of therapies tailored to specific tumor heterogeneity and patient profiles.
  • Innovative drug modalities—including antibody-drug conjugates and CAR T cell therapies—expand treatment options for prevalent and refractory tumor subtypes.
  • Adaptive clinical trials and patient-centric, decentralized models are optimizing timelines and access, generating richer safety and efficacy data for regulatory submissions.
  • Operational and supply chain strategies are evolving via regional partnerships, alternative sourcing, and stockpiling to counteract potential cost increases linked to tariff shifts.
  • Collaborative business models, such as joint ventures and licensing agreements between biotech, academia, and industry, accelerate innovation and maximize development capacity.

Tariff Impact and Strategic Responses

Recent United States tariff changes have introduced additional complexity to the solid tumor protein research and manufacturing supply chain. Stakeholders are responding by diversifying sourcing, adopting nearshore manufacturing, and renegotiating contracts to contain rising production costs. Shared infrastructure models, as well as formulation innovations to reduce reliance on imported excipients, support continued progress in discovery and clinical programs. Integration of tariff forecasting into procurement and risk planning is essential for ongoing operational resilience and resource optimization.

Methodology & Data Sources

This analysis synthesizes primary interviews with oncology experts, drug developers, and regulators, together with stakeholder surveys, to capture both qualitative context and real-world challenges. Secondary research encompasses clinical trial registries, peer-reviewed literature, patent filings, and regulatory documents, validated through cross-functional expert review cycles to ensure robust, actionable insight.

Why This Report Matters for Senior Decision-Makers

  • Aligns investment and R&D strategy with the evolving landscape of molecular targeting and immuno-oncology integration.
  • Highlights supply chain risk mitigation, operational best practices, and technology adoption opportunities across major global regions.
  • Enables efficient benchmarking of clinical, commercial, and regulatory trends to inform competitive positioning and future portfolio development.

Conclusion

Senior leaders in the oncology sector are equipped to navigate the intersection of molecular innovation, regulatory change, and market-driven operational strategies by leveraging this report. The convergence of scientific advances, strategic alliances, and patient-centered models will define the future trajectory of solid tumor target protein therapeutics.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Integration of bispecific antibodies targeting EGFR and MET to overcome resistance in solid tumors
5.2. Advancements in proteomic profiling for personalized target protein selection in solid tumor therapies
5.3. Emergence of next generation antibody drug conjugates with cleavable linkers for precise payload delivery in solid neoplasms
5.4. Strategic development of proteolysis targeting chimeras for degradation of KRAS mutants in pancreatic and colorectal cancers
5.5. Implementation of in silico protein docking algorithms for accelerated identification of novel solid tumor targets and inhibitors
5.6. Adoption of multiomics biomarker panels combining phosphoproteomics and genomics to stratify responders in immuno-oncology trials
5.7. Progress in engineering tumor microenvironment modulating agents that target stromal proteins to enhance drug penetration in desmoplastic solid tumors
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Solid Tumors Target Proteins Market, by Indication
8.1. Introduction
8.2. Breast Cancer
8.2.1. Her2 Positive
8.2.2. Hormone Receptor Positive
8.2.3. Triple Negative
8.3. Colorectal Cancer
8.4. Lung Cancer
8.4.1. Non-Small Cell Lung Cancer
8.4.2. Small Cell Lung Cancer
8.5. Ovarian Cancer
8.6. Prostate Cancer
9. Solid Tumors Target Proteins Market, by Target Class
9.1. Introduction
9.2. Checkpoint Inhibitors
9.2.1. Ctla-4
9.2.2. Pd-1
9.2.3. Pd-L1
9.3. Dna Repair Proteins
9.4. Growth Factor Receptors
9.4.1. Egfr
9.4.2. Her2
9.4.3. Vegfr
9.5. Kinase Inhibitors
9.5.1. Serine Threonine Kinase Inhibitors
9.5.2. Tyrosine Kinase Inhibitors
9.6. Nuclear Receptors
10. Solid Tumors Target Proteins Market, by Therapeutic Modality
10.1. Introduction
10.2. Antibody Drug Conjugates
10.3. Car T
10.4. Monoclonal Antibodies
10.4.1. Chimeric
10.4.2. Fully Human
10.4.3. Humanized
10.5. Small Molecules
11. Solid Tumors Target Proteins Market, by Mechanism of Action
11.1. Introduction
11.2. Allosteric Inhibitors
11.3. Dna Damage Agents
11.4. Hormone Receptor Antagonists
11.5. Immune Checkpoint Blockers
11.6. Receptor Tyrosine Kinase Inhibitors
12. Americas Solid Tumors Target Proteins Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Solid Tumors Target Proteins Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Solid Tumors Target Proteins Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Merck & Co., Inc.
15.3.2. F. Hoffmann-La Roche Ltd.
15.3.3. Bristol-Myers Squibb Company
15.3.4. AstraZeneca PLC
15.3.5. Pfizer Inc.
15.3.6. Novartis AG
15.3.7. Johnson & Johnson
15.3.8. Amgen Inc.
15.3.9. AbbVie Inc.
15.3.10. Sanofi S.A.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. SOLID TUMORS TARGET PROTEINS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2024 VS 2030 (%)
FIGURE 10. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. SOLID TUMORS TARGET PROTEINS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. SOLID TUMORS TARGET PROTEINS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. SOLID TUMORS TARGET PROTEINS MARKET: RESEARCHAI
FIGURE 24. SOLID TUMORS TARGET PROTEINS MARKET: RESEARCHSTATISTICS
FIGURE 25. SOLID TUMORS TARGET PROTEINS MARKET: RESEARCHCONTACTS
FIGURE 26. SOLID TUMORS TARGET PROTEINS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. SOLID TUMORS TARGET PROTEINS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY HER2 POSITIVE, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY HER2 POSITIVE, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TRIPLE NEGATIVE, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TRIPLE NEGATIVE, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY SMALL CELL LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY SMALL CELL LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CTLA-4, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CTLA-4, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY PD-1, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY PD-1, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY PD-L1, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY PD-L1, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY DNA REPAIR PROTEINS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY DNA REPAIR PROTEINS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY EGFR, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY EGFR, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY HER2, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY HER2, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY VEGFR, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY VEGFR, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY SERINE THREONINE KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY SERINE THREONINE KINASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY NUCLEAR RECEPTORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY NUCLEAR RECEPTORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CAR T, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CAR T, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHIMERIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHIMERIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY FULLY HUMAN, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY FULLY HUMAN, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY HUMANIZED, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY ALLOSTERIC INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY ALLOSTERIC INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY DNA DAMAGE AGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY DNA DAMAGE AGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY HORMONE RECEPTOR ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY HORMONE RECEPTOR ANTAGONISTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY RECEPTOR TYROSINE KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY RECEPTOR TYROSINE KINASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2025-2030 (USD MILLION)
TABLE 115. AMERICAS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 116. AMERICAS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 117. AMERICAS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 118. AMERICAS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 119. AMERICAS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 120. AMERICAS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 121. UNITED STATES SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 122. UNITED STATES SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 123. UNITED STATES SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 124. UNITED STATES SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 125. UNITED STATES SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 126. UNITED STATES SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 127. UNITED STATES SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2018-2024 (USD MILLION)
TABLE 128. UNITED STATES SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2025-2030 (USD MILLION)
TABLE 129. UNITED STATES SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 130. UNITED STATES SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 131. UNITED STATES SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2018-2024 (USD MILLION)
TABLE 132. UNITED STATES SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2025-2030 (USD MILLION)
TABLE 133. UNITED STATES SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 134. UNITED STATES SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 135. UNITED STATES SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2024 (USD MILLION)
TABLE 136. UNITED STATES SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2025-2030 (USD MILLION)
TABLE 137. UNITED STATES SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 138. UNITED STATES SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 139. UNITED STATES SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 140. UNITED STATES SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 141. UNITED STATES SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 142. UNITED STATES SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 143. CANADA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 144. CANADA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 145. CANADA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 146. CANADA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 147. CANADA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 148. CANADA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 149. CANADA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2018-2024 (USD MILLION)
TABLE 150. CANADA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2025-2030 (USD MILLION)
TABLE 151. CANADA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 152. CANADA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 153. CANADA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2018-2024 (USD MILLION)
TABLE 154. CANADA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2025-2030 (USD MILLION)
TABLE 155. CANADA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 156. CANADA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 157. CANADA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2024 (USD MILLION)
TABLE 158. CANADA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2025-2030 (USD MILLION)
TABLE 159. CANADA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 160. CANADA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 161. CANADA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 162. CANADA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 163. MEXICO SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 164. MEXICO SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 165. MEXICO SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 166. MEXICO SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 167. MEXICO SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 168. MEXICO SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 169. MEXICO SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2018-2024 (USD MILLION)
TABLE 170. MEXICO SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2025-2030 (USD MILLION)
TABLE 171. MEXICO SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 172. MEXICO SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 173. MEXICO SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2018-2024 (USD MILLION)
TABLE 174. MEXICO SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2025-2030 (USD MILLION)
TABLE 175. MEXICO SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 176. MEXICO SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 177. MEXICO SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2024 (USD MILLION)
TABLE 178. MEXICO SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2025-2030 (USD MILLION)
TABLE 179. MEXICO SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 180. MEXICO SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 181. MEXICO SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 182. MEXICO SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 183. BRAZIL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 184. BRAZIL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 185. BRAZIL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 186. BRAZIL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 187. BRAZIL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 188. BRAZIL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 189. BRAZIL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2018-2024 (USD MILLION)
TABLE 190. BRAZIL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2025-2030 (USD MILLION)
TABLE 191. BRAZIL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 192. BRAZIL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 193. BRAZIL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2018-2024 (USD MILLION)
TABLE 194. BRAZIL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2025-2030 (USD MILLION)
TABLE 195. BRAZIL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 196. BRAZIL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 197. BRAZIL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2024 (USD MILLION)
TABLE 198. BRAZIL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2025-2030 (USD MILLION)
TABLE 199. BRAZIL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 200. BRAZIL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 201. BRAZIL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 202. BRAZIL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 203. ARGENTINA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 204. ARGENTINA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 205. ARGENTINA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 206. ARGENTINA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 207. ARGENTINA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 208. ARGENTINA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 209. ARGENTINA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2018-2024 (USD MILLION)
TABLE 210. ARGENTINA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2025-2030 (USD MILLION)
TABLE 211. ARGENTINA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 212. ARGENTINA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 213. ARGENTINA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2018-2024 (USD MILLION)
TABLE 214. ARGENTINA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2025-2030 (USD MILLION)
TABLE 215. ARGENTINA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 216. ARGENTINA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 217. ARGENTINA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2024 (USD MILLION)
TABLE 218. ARGENTINA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2025-2030 (USD MILLION)
TABLE 219. ARGENTINA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 220. ARGENTINA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 221. ARGENTINA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 222. ARGENTINA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 223. EUROPE, MIDDLE EAST & AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 224. EUROPE, MIDDLE EAST & AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 225. EUROPE, MIDDLE EAST & AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 226. EUROPE, MIDDLE EAST & AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 227. EUROPE, MIDDLE EAST & AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 228. EUROPE, MIDDLE EAST & AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 229. EUROPE, MIDDLE EAST & AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2018-2024 (USD MILLION)
TABLE 230. EUROPE, MIDDLE EAST & AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2025-2030 (USD MILLION)
TABLE 231. EUROPE, MIDDLE EAST & AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 232. EUROPE, MIDDLE EAST & AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 233. EUROPE, MIDDLE EAST & AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2018-2024 (USD MILLION)
TABLE 234. EUROPE, MIDDLE EAST & AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2025-2030 (USD MILLION)
TABLE 235. EUROPE, MIDDLE EAST & AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 236. EUROPE, MIDDLE EAST & AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 237. EUROPE, MIDDLE EAST & AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2024 (USD MILLION)
TABLE 238. EUROPE, MIDDLE EAST & AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2025-2030 (USD MILLION)
TABLE 239. EUROPE, MIDDLE EAST & AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 240. EUROPE, MIDDLE EAST & AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 241. EUROPE, MIDDLE EAST & AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 242. EUROPE, MIDDLE EAST & AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 243. EUROPE, MIDDLE EAST & AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 244. EUROPE, MIDDLE EAST & AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 245. UNITED KINGDOM SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 246. UNITED KINGDOM SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 247. UNITED KINGDOM SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 248. UNITED KINGDOM SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 249. UNITED KINGDOM SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 250. UNITED KINGDOM SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 251. UNITED KINGDOM SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2018-2024 (USD MILLION)
TABLE 252. UNITED KINGDOM SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2025-2030 (USD MILLION)
TABLE 253. UNITED KINGDOM SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 254. UNITED KINGDOM SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 255. UNITED KINGDOM SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2018-2024 (USD MILLION)
TABLE 256. UNITED KINGDOM SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2025-2030 (USD MILLION)
TABLE 257. UNITED KINGDOM SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 258. UNITED KINGDOM SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 259. UNITED KINGDOM SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2024 (USD MILLION)
TABLE 260. UNITED KINGDOM SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2025-2030 (USD MILLION)
TABLE 261. UNITED KINGDOM SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 262. UNITED KINGDOM SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 263. UNITED KINGDOM SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 264. UNITED KINGDOM SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 265. GERMANY SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 266. GERMANY SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 267. GERMANY SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 268. GERMANY SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 269. GERMANY SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 270. GERMANY SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 271. GERMANY SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2018-2024 (USD MILLION)
TABLE 272. GERMANY SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2025-2030 (USD MILLION)
TABLE 273. GERMANY SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 274. GERMANY SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 275. GERMANY SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2018-2024 (USD MILLION)
TABLE 276. GERMANY SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2025-2030 (USD MILLION)
TABLE 277. GERMANY SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 278. GERMANY SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 279. GERMANY SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2024 (USD MILLION)
TABLE 280. GERMANY SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2025-2030 (USD MILLION)
TABLE 281. GERMANY SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 282. GERMANY SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 283. GERMANY SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 284. GERMANY SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 285. FRANCE SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 286. FRANCE SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 287. FRANCE SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 288. FRANCE SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 289. FRANCE SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 290. FRANCE SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 291. FRANCE SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2018-2024 (USD MILLION)
TABLE 292. FRANCE SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2025-2030 (USD MILLION)
TABLE 293. FRANCE SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 294. FRANCE SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 295. FRANCE SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2018-2024 (USD MILLION)
TABLE 296. FRANCE SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2025-2030 (USD MILLION)
TABLE 297. FRANCE SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 298. FRANCE SOLID TUMORS TARGET PROTEINS MARKET S

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Solid Tumors Target Proteins market report include:
  • Merck & Co., Inc.
  • F. Hoffmann-La Roche Ltd.
  • Bristol-Myers Squibb Company
  • AstraZeneca PLC
  • Pfizer Inc.
  • Novartis AG
  • Johnson & Johnson
  • Amgen Inc.
  • AbbVie Inc.
  • Sanofi S.A.

Related Reports

Bispecific Antibodies Market - Global Forecast to 2030 - Product Image

Bispecific Antibodies Market - Global Forecast to 2030

  • Report
  • 188 Pages
  • Global
From
Immuno-oncology Clinical Trials Market - Global Forecast 2025-2030 - Product Image

Immuno-oncology Clinical Trials Market - Global Forecast 2025-2030

  • Report
  • 197 Pages
  • Global
From
Checkpoint Inhibitor Refractory Cancer Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Checkpoint Inhibitor Refractory Cancer Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From
Checkpoint Inhibitor Refractory Cancer - Global Strategic Business Report - Product Image

Checkpoint Inhibitor Refractory Cancer - Global Strategic Business Report

  • Report
  • 287 Pages
  • Global
From
Checkpoint Inhibitors Market Report 2025 - Product Image

Checkpoint Inhibitors Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.